President Trump’s administration marked a policy milestone on drug pricing deals while Regeneron simultaneously announced a related gene therapy approval. The administration said it closed a first round of drug pricing agreements and pushed additional steps for TrumpRx pricing. Separately, Regeneron said Otarmeni—its hearing loss gene therapy—was approved by the FDA under the National Priority Voucher program, with the company planning to offer the treatment at no cost to American patients. In the backdrop, the White House’s approach is centered on tying prices to low global benchmarks. The pairing underscores how pricing policy and accelerated regulatory mechanisms are increasingly operating together in the U.S. market, shaping both access and development incentives for high-cost biologics and gene therapies.